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A B S T R A C T
Purpose
Downstaging (DS) of rectal cancers is achieved in approximately 45% of patients with neoadjuvant
fluorouracil (FU) -based chemoradiotherapy (CRT). Polymorphisms in the thymidylate synthase
gene (TYMS) had previously defined two risk groups associated with disparate tumor DS rates
(60% v 22%). We conducted a prospective single-institution phase II study using TYMS
genotyping to direct neoadjuvant CRT for patients with rectal cancer.
Patients and Methods
Patients with T3/T4, N0-2, M0-1 rectal adenocarcinoma were evaluated for germline TYMS
genotyping. Patients with TYMS *2/*2, *2/*3, or *2/*4 (good risk) were treated with standard
chemoradiotherapy using infusional FU at 225 mg/m2/d. Patients with TYMS *3/*3 or *3/*4 (poor
risk) were treated with FU/RT plus weekly intravenous irinotecan at 50 mg/m2. The primary end
point was pathologic DS. Secondary end points included complete tumor response (ypT0), toxicity,
recurrence rates, and overall survival.
Results
Overall, 135 patients were enrolled, of whom 27.4% (37 of 135) were considered poor risk. The
prespecified statistical goals were achieved, with DS and ypT0 rates reaching 64.4% and 20% for
good-risk and 64.5% and 42% for poor-risk patients, respectively.
Conclusion
To our knowledge, this is the first study to prospectively use TYMS genotyping to direct
neoadjuvant CRT in patients with rectal cancer. High rates of DS and ypT0 were achieved among
both risk groups when personalized treatment was based on TYMS genotype. These results are
encouraging, and further evaluation of this genotype-based strategy using a randomized study
design for locally advanced rectal cancer is warranted.
J Clin Oncol 29:875-883. © 2011 by American Society of Clinical Oncology
INTRODUCTION
Colorectal cancer (CRC) is the third most common
cancer diagnosis among both sexes, with an esti-
mated 142,570 new cases and approximately 51,370
deaths in the United States in 2010.1 Of these, 27.8%
are rectal cancers. Neoadjuvant fluoropyrimidine-
based chemoradiotherapy (CRT) is the standard
therapy for patients with locally advanced rectal ad-
enocarcinoma.2,3 Preoperative treatment was asso-
ciated with lower risk of local recurrence and lower
toxicities compared with radiotherapy (RT) alone4-6
or postoperative CRT.2,3 Preoperative chemoradio-
therapy resulted in tumor T stage downstaging (DS)
rates of approximately 45% (40% to 60%)7-12 and a
pathologic complete response (pCR) rate of 15% to
30%.3,8-13 Pathologic DS or a pCR after preoperative
CRT has been correlated with improved survival,
decreased recurrence, and a higher rate of sphincter-
preserving surgeries.9,14-17
Thymidylate synthase (TS) is critical in DNA
synthesis and serves as the primary target of fluorou-
racil (FU). Its overexpression has been linked to
resistance to fluoropyrimidine-based chemotherapy
in numerous cancers.18-23 The TS gene (TYMS)
contains a tandem repeat consisting of 28–base pair
repeat units found in the 5 untranslated region,
which acts as an enhancer to the TYMS promoter
(TS enhancer region [TSER]). In vitro and in vivo
studies have shown that higher number of repeats
(from TSER*2 to TSER*3 or higher) led to stepwise
increases in TS expression24,25 and activity.26
TSER*3 homozygosity seems to be associated
with a lower response to neoadjuvant FU-based
CRT for patients with rectal cancer. Villafranca et
al27 examined 65 patients with locally advanced
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rectal cancer treated with FU-based preoperative CRT. Patients
with the TSER*3/*3 genotype achieved a DS rate of only 22%
compared with 60% for those patients with either the TSER*2/*2
or TSER*2/*3 genotypes. Later, Spindler et al28 demonstrated
that patients with the TSER*2/*2 genotype experienced a 53%
pCR compared with 26% for those with TSER*2/*3 and only
17% for patients with the TSER*3/*3 variants. The negative effect
of the TSER*3 allele was also observed on survival of patients with
locally advanced gastric cancer treated with neoadjuvant FU-
based chemotherapy.29
Thus we conducted a prospective nonrandomized single-
institution tandem phase II study using TYMS genotyping to direct
neoadjuvant CRT for patients with locally advanced and metastatic
rectal cancer. Patients with germline TSER*2/*2 or TSER*2/*3,
deemed good risk for a favorable response to FU, were treated with
standard CRT. Poor-risk patients (TSER*3/*3 or TSER*3/*4 geno-
types) who were unlikely to derive significant benefit from FU
chemotherapy were treated with irinotecan in addition to standard
FU/CRT. The primary end point of this study was to determine
whether TYMS genotype-directed neoadjuvant CRT would result in
greater rates of tumor DS compared with those predicted among
historical controls. The secondary end points were to assess the com-
plete pathologic response rates, toxicities, recurrence rates, and sur-
vival of both regimens.
PATIENTS AND METHODS
Eligibility
Patients 18 years or older, with biopsy-proven clinical T3/T4, N0-2,
M0-1 adenocarcinoma of the rectum and a Karnofsky performance status of
60% or more were eligible. Inclusion and exclusion criteria are described in the
Appendix (online only).
Study Design and Treatment
This is a single-institution, multidisciplinary, prospective, tandem, phase
II nonrandomized study using TYMS genotyping to direct neoadjuvant CRT
for patients with rectal cancer (Fig 1). Before treatment, clinical staging was
performed, blood samples were obtained, and TSER polymorphisms were
evaluated using a previously described polymerase chain reaction–based as-
say.30 Patients carrying at least one *2 allele (TSER*2/*2, *2/*3, or *2/*4) were
assigned to the good-risk genotype group (study 1) and treated with standard
preoperative CRT. Radiotherapy consisted of a total of 45 to 50.4 Gy delivered
in 25 to 28 fractions (1.80 to 2.0 Gy per fraction) by a multiple-field technique
using image-guided radiotherapy with radiotherapy target volume consistent
with the Radiation Therapy Oncology Group consensus guidelines.31 The
administration of additional boost radiation for a total of 50.4 Gy was done at
the discretion of the treating radiation oncologist. Concurrent continuous
intravenous infusion of FU at a dose of 225 mg/m2/d was administered
throughout radiation with no weekend breaks. Patients with TSER*3/*3 or
TSER*3/*4 were assigned to the poor-risk genotype group (study 2) and
treated with weekly intravenous irinotecan at 50 mg/m2 for 5 weeks in addition
to standard CRT identical to the treatment in the good-risk group. Clinical
restaging and resection of the primary rectal lesion were performed 6 to 10
weeks after completion of preoperative CRT. Additional therapy, whether
adjuvant or for metastatic disease, were administered at the discretion of the
treating physician.
Assessment of Efficacy and Toxicity
Baseline clinical tumor staging using rigid proctoscopy, transrectal
ultrasound (TRUS), spiral computed tomography (CT), or magnetic res-
onance imaging (MRI) were performed within 28 days of enrollment.
During CRT, weekly physical examination, toxicity assessment, CBC, and
comprehensive metabolic panel were done. Clinical restaging with TRUS,
CT, or MRI was repeated before resection. The surgical procedure per-
formed was at the discretion of the treating surgical oncologist. Standard-
ized institutional pathology examinations based on Westra et al32 were
done, and the pathologic staging, as well as extent of residual tumor in the
resected specimen, was classified using the American Joint Committee on
Cancer version 6 criteria. Tumor DS was defined as a decrease in the T stage
of the primary tumor by at least 1. Complete tumor response was defined as
the absence of any viable tumor in the rectum (ypT0). pCR was defined as
the absence of any viable tumor in the rectum or in the perirectal lymph
nodes (ypT0N0). Toxicities were graded according to the National Cancer
Institute Common Toxicity Criteria version 2.0.
Dose adjustments (described in the Appendix, online only) were made as
per a study-defined dose modification table depending on the type and severity
of toxicities associated with study treatment.
Statistical Analyses
The primary end point was the rates of tumor DS among good-risk and
poor-risk groups. Secondary end points include ypT0 rate, toxicity, overall
survival (OS, and relapse-free survival (RFS). The two-stage study design
proposed by Simon33 was used for sample size calculations for both groups:
good-risk genotype (study 1) and poor-risk genotype (study 2). On the basis of
both local and literature data, the DS rate for the general T3/T4 population was
set at 45% with conventional therapy,7,8,10,12 and the predicted DS rate for
good-risk TYMS was 60%.27 Study 1 required a sample size of 77 good-risk
patients to have an 80% power at a significance level of .05 to reject a DS rate of
less than 45% in favor of a DS rate of  60%. Study 2 assumed that the DS
rate is 22% for poor-risk genotype patients with conventional therapy.27 A
sample size of 31 patients was necessary to reject a DS rate of 22% in favor
of a DS rate of  45% with a power of 80% power at a significance level of
.05. Baseline characteristics between good- and poor-risk groups have been
compared with a t test for age and with Fisher’s exact tests for all other
characteristics. The proportion of patients with DS within each risk group
was compared with historical rates by using one sample binomial tests. OS































Fig 1. TYMS genotype-directed neoadju-
vant chemoradiotherapy study outline. RT,
radiotherapy; FU, fluorouracil; Cpt-11, irinote-
can; TRUS, transrectal ultrasound; CT, com-
puted tomography; MRI, magnetic resonance
imaging.
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Table 1. Baseline Patient and Tumor Characteristics (n  135)
Characteristic
All Patients Good Risk Poor Risk
PNo. % No. % No. %
No. of patients 135 100 98 72.6 37 27.4
TSER genotype
2/ 2 26 26.5
2/ 3 71 72.5
2/ 4 1 1.0
3/ 3 35 94.6
3/ 4 2 5.4
Age, years
Median 56 55 59 .64
Range 26-85 32-85 26-77
Race/ethnicity
White 115 85.2 86 87.8 29 78.4
African American 18 13.3 10 10.2 8 21.6
Hispanic 1 0.7 1 1.0 —
Asian 1 0.7 1 1.0 — .18
Sex
Male 93 68.9 69 70.4 24 64.9
Female 42 31.1 29 29.6 13 35.1 .54
ECOG performance status
0 89 65.9 63 64.3 26 70.3
1 45 33.3 34 34.7 11 29.7
2 1 0.7 1 1.0 0 .55†
Baseline stage
Stage IIA (T3, N0, M0) 34 25.2 24 24.5 10 27.0
Stage IIB (T4, N0, M0) 3 2.2 3 3.1 0
Stage IIIA (T1-2, N1, M0) 1 0.7 1 1.0 0
Stage IIIB (T3-4, N1, M0) 72 53.3 53 54.1 19 51.4
Stage IIIC (T-any, N2, M0) 6 4.4 3 3.1 3 8.1
Stage IV (T-any, N-any, M1) 19 14.1 14 14.3 5 13.5 .66‡
Baseline clinical T stage
T1-2 2 1.5 2 2.0 0
T3 109 80.7 77 78.6 32 86.5
T4 24 17.8 19 19.4 5 13.5 .64
Baseline clinical N stage
N0 41 30.4 30 30.6 11 29.8
N1 86 63.7 64 65.3 22 59.5
N2 8 5.9 4 4.1 4 10.8 .36
Baseline clinical M stage
M0 116 85.9 84 85.7 32 86.5
M1 19 14.1 14 14.3 5 13.5 .99
Clinical staging modality
EUS 81 60 60 61.2 21 56.8
CT  PET 28 20.7 22 22.5 6 16.2
MRI 26 19.3 16 16.3 10 27.1 .35
Tumor distance from anal verge, cm
 5 45 33.3 33 33.7 12 32.4
5-10 78 57.8 57 58.2 21 56.8
 10 12 8.9 8 8.2 4 10.8 .91
Tumor grade
Well differentiated 12 8.9 8 8.2 4 10.8
Moderately differentiated 93 68.9 58 69.4 25 67.6
Poorly differentiated 24 17.8 17 17.3 7 19.9
Not reported 6 4.4 5 5.1 1 2.7 .95
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EUS, endoscopic ultrasound; CT, computed tomography; PET, positron emission tomography; MRI,
magnetic resonance imaging.
Race is compared in two categories, white versus other.
†ECOG performance status is compared in two categories, 0 versus 1 or 2.
‡Baseline stage is compared in four categories: IIA or IIB versus IIIA or IIIB versus IIIC versus IV.
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presence/absence of downstaging were compared with log-rank tests gen-
erated by Kaplan-Meier models.
RESULTS
Patient Characteristics
Patient baseline characteristics are listed in Table 1. Between
February 2003 and July 2008, 135 patients with rectal cancer were
enrolled onto the trial; 98 patients (72.6%) had good-risk genotypes
(TSER *2/*2, *2/*3, or *2/*4), whereas 37 patients (27.4%) had poor-
risk genotypes (TSER *3/*3, *3/*4). Clinical staging was performed
using physical findings plus TRUS (60%), CT (20%), and MRI (20%)
of patients. There was no difference in baseline characteristics between
the good-risk and poor-risk groups. Fourteen percent of patients had
metastatic disease on enrollment. Four patients, two from each group,
withdrew consent before any study treatment and were excluded from
analysis of the primary and secondary end points.
Treatment
Ninety-six of the 98 good-risk patients received standard CRT
using infusional FU (225 mg/m2 per day) throughout radiation. Two
patients withdrew consent and were not treated.
Dose delays and dose reduction of FU occurred in 19 (20%) of 96
patients treated, mostly secondary to mucositis or enteritis. Thirty-
four of the 37 poor-risk patients received weekly irinotecan with
standard FU and radiation. Two patients were not treated because of
Table 2. Grade 3 to 4 Toxicities and Hospitalizations Related to Treatment and Surgery (occurring within 30 days of surgery)
Toxicity
All Patients Good Risk Poor Risk
No. % No. % No. %
No. of patients 135 98 37
Evaluable patients 131 96 35
Death on protocol 2 1 (myocardial infarction) 1 (aneurysmal bleed)
Hospitalization
Diarrhea/RT enteritis 14 10.7 7 7
Perforation/abscess/leak fistula 4 3.1 2 2
Pneumonia 1 0.8 0 1
Febrile neutropenia 1 0.8 0 1
Aneurysmal bleed 1 0.8 0 1
Atrial fibrillation 1 0.8 1 0
Myocardial infarction 1 0.8 1 0
Gastrointestinal bleed 1 0.8 1 0
Anemia-blood transfusion 1 0.8 1 0
Hypoglycemia 1 0.8 1 0
Hernia repair 1 0.8 1 0
Crohn’s flare 1 0.8 1 0
Total 28 21.4 16/96 16.7 12/35 34.3
Grade 3-4 toxicities
Nausea 1 1.0 1 2.9
Vomiting 1 1.0 1 2.9
Diarrhea 33 25.2 17 17.7 16 45.7
Dehydration 10 7.0 3 3.2 7 20.0
Mucositis 5 3.9 4 4.2 1 2.9
GI bleed 2 1.6 2 2.1
Ileitis 1 1.0 1 2.9
Enteritis 1 1.0 1 1.0
Dyspnea 1 0.8 1 1.0
Neutropenia 1 1.0 1 2.9
Anemia 6 4.6 3 3.1 3 8.8
Pain 7 5.3 3 3.1 4 11.4
Perforation 3 2.3 2 2.1 1 2.9
Pelvic abscess 2 1.6 2 5.7
PPE 1 1.0 1 2.9
Crohn’s flare 1 1.0 1 1.0
Syncope 2 1.6 2 2.1
Rash 2 1.6 2 2.1
Fatigue 1 1.0 1 1.0
Atrial fibrillation 1 1.0 1 1.0
Infection 2 1.6 1 1.0 1 2.9
Headache 1 1.0 1 1.0
Small bowel obstruction 1 1.0 1 1.0
Abbreviations: RT, radiotherapy; PPE, palmar-plantar erythrodysesthesia.
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consent withdrawal. One patient received only standard FU chemo-
radiotherapy without irinotecan because of physician error. A total of
149 doses of irinotecan were given (mean, four doses/patient; range,
zero to six doses). Chemotherapy dose delays and dose reduction
secondary to toxicities occurred in 19 (51.4%) of 37 patients treated.
Four patients (two in each group) did not receive the full intended
course of radiation.
Toxicities
Two deaths occurred on protocol: one patient in the good-risk
group died as a result of a myocardial infarction, and another patient
in the poor-risk group died as a result of an aneurysmal bleed. As
shown in Table 2, 131 patients were evaluable for toxicity. Among the
96 evaluable patients in the good-risk arm, hospitalization rates were
16% as compared with 34% among the 35 evaluable poor-risk
patients. In the poor-risk group, 19 (54.3%) of the 35 patients experi-
enced grade 3 or 4 toxicities compared with 30.2% in the good-risk
group. The incidence of grade 3 or greater diarrhea was higher in the
poor-risk group (45.7%) treated with irinotecan-based chemoradio-
therapy as compared with good-risk patients treated with FU and
radiation alone (17.7%). Regarding the immediate postoperative tox-
icities, nine (9.9%) of the 91 patients who underwent resection in the
good-risk group developed the following complications: abscess
(n  4), anastomotic leak (n  3), and fistula formation (n  2).
Among the 31 patients treated with irinotecan-based chemoradio-
therapy in the poor-risk group, four (12.9%) had abscess formation.
Surgery
Ninety-one (93%) of the 98 patients in the good-risk group and
32 (86%) of the 37 patients in the poor-risk group underwent surgery,
Table 3. Surgery Procedures and Tumor Downstaging
Surgery and Stage
Good Risk Poor Risk
No. % No. %
No. of patients 98 37
Type of surgery
Lower anterior resection 71 72.5 22† 59.5
Abdominoperineal resection 15 15.3 9 24.3
Total proctocolectomy 4 4.1 1 2.7
Pelvic exenteration 1 1.0 0
Treated but no surgery 5‡ 5.1 3§ 8.1
Consent withdrawal or insurance denial 2 2.0 2 5.4
No. of patients with positive margins 4 of 91 4.4 4 of 32 12.5
Evaluable patients for downstaging 90 31
Nonevaluable patients for downstaging 8 6
Death prior to surgery 1 1
Clinical CR, no surgery 1 1
Refused surgery 1 1
Not resectable 2 0
Consent withdrawal or insurance denial 2 2
Delayed surgery and given FOLFOX before surgery 1 (pCR) 0
Not given irinotecan by treating physician NA 1
Post-treatment stage for evaluable patients 90 31
Stage 0 16 18.7 9 29.0
Stage I (T1-T2 N0 M0) 27 30.0 7 22.6
Stage II (T3-T4 N0M0) 12 13.3 5 16.1
Stage III (T-any N1-2 M0) 22 24.4 6 19.4
Stage IV (T-any N-any M1) 13 14.4 4 12.9
T stage
T0 18 20.0 13 41.9
T1-2 34 37.8 7 22.6
T3-4 38 42.2 11 35.5
N stage
N0 61 67.8 24 77.4
N1 20 22.2 5 16.1
N2 9 10.0 2 6.5
T-stage downstaging 58 64.4 20 64.5
ypT0 18 20.0 13 41.9
Pathologic complete response (ypT0N0) 17 18.9 11 35.5
Abbreviations: CR, complete response; FOLFOX, infusional fluorouracil, leucovorin, and oxaliplatin; pCR, pathologic complete response; NA, not applicable.
One patient had delayed surgery as a result of morbid obesity and received FOLFOX and had a complete pathologic response.
†One patient who underwent lower anterior resection was not evaluable as a result of not receiving irinotecan.
‡One patient died as a result of myocardial infarction before surgery, one patient had a clinical complete response and did not undergo surgery, one patient refused
surgery, and two patients were found to have unresectable disease during exploratory laparotomy.
§One patient died before surgery, one patient had clinical complete response and did not undergo surgery, and one patient refused surgery.
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with a mean resection rate of 91% for the whole group. Surgery
procedures are presented in Table 3. The median time from comple-
tion of chemoradiotherapy to surgery was 57 days (range, 9 to 187
days), with no difference between the good-risk group (57 days) and
the poor-risk group (59 days). One patient had a delayed surgery (187
days after the end of chemotherapy) because of morbid obesity.
Among patients who underwent resection, sphincter-saving surgery
was performed in 71 (78%) of 91 patients in the good-risk group and
in 22 (69%) of 32 patients in the poor-risk group.
Response to Neoadjuvant Chemoradiotherapy
Response to neoadjuvant CRT, including DS results, are pre-
sented in Table 3. Among the 98 patients with good-risk genotype
enrolled, eight were nonevaluable for response (Table 3). Of the 90
evaluable patients, 58 (64.4%) had T-stage DS (95% CI, 54.1% to
74.6%; P  .0001). Rates for ypT0 and pCR were 20% and 18.9%.
Within the good-risk group, patients with TSER *2/*2 experienced
similar DS and ypT0 rates (64% and 20%) compared with those with
TSER *2/*3 or *2/*4 (64% and 20%). The nonevaluable good-risk
patient who had four doses of oxaliplatin-based chemotherapy before
surgery had a pCR (ypT0N0).
Among the 37 patients with poor-risk genotype, six were non-
evaluable for response (Table 3). For the 31 evaluable patients, T-stage
DS was achieved in 20 patients (64.5%; 95% CI, 43.7% to 78.9%;
P  .0001). Rates for ypT0 and pCR were 41.9% and 35.5%. The
nonevaluable poor-risk patient who did not receive irinotecan did not
have tumor DS. Post-treatment pathologic stage is shown in Table A1
(Appendix, online only).
Recurrence and Survival
RFS and OS data were monitored as secondary objectives. After a
median follow-up period of 45 months, 97 (74%) of the evaluable 131
patients remain alive. RFS and OS plots for both good- and poor-risk
groups are shown in Figures 2A and 2B.
Among the 96 evaluable good-risk patients, 14 had metastatic
rectal cancer at the time of enrollment. Median survival for all 96
patients has not yet been reached. One-year, 2-year, and 3-year OS
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Fig 2. Kaplan-Meier curves showing (A, C) relapse-free survival and (B, D) overall survival by groups (A, B) and according to the existence of a pathologic complete
response (ypT0), a tumor downstaging (DS; including patients with ypT0), or no DS (C, D). A and B include 131 patients; C and D correspond to patients with
nonmetastatic disease only (n  110).
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nonmetastatic patients (stages II and III), 17 patients have died and 22
patients have experienced recurrence. One-year, 2-year, and 3-year
OS rates were 97.6%, 84.8%, and 82%, respectively. One-year, 2-year,
and 3-year RFS rates were 85.2%, 78.3%, and 73.4%, respectively.
Among the patients who experienced recurrence, only one patient
(4.5%) had a local recurrence, and 21 patients (95.5%) had distant
recurrence (mainly lung and liver metastasis) in the good-risk group.
Among the 35 evaluable poor-risk patients, three patients had
stage IV disease before surgery. Median survival for all poor-risk
patients has not been reached. One-year, 2-year, and 3-year OS rates
were 94.3%, 94.3%, and 83.6%, respectively. For the 32 patients with
no metastatic disease at the time of enrollment, 1-, 2- and 3-year RFS
and OS are as follows: 87% and 93.8%, 80.5% and 93.8%, and 72.4%
and 81.8%, respectively. Regarding the recurrences, one patient (10%)
had a local recurrence, and nine patients (90%) had distant recurrence
(mainly lung and liver metastasis) in the poor-risk group.
Regardless of genotype risk group, patients who achieved any
downstaging, including those with ypT0, had significantly improved
RFS and OS as compared with patients with no DS. Those who
achieved ypT0 have the best outcomes. The differences in RFS and OS
observed between patients with or without DS were statistically signif-
icant in all patients (P  .0003 and P  .0185 respectively, data not
shown) and in nonmetastatic patients (P  .0005 and P  .0444; Figs
2C and 2D).
DISCUSSION
This genotype-driven study demonstrated that the prospective use of
pharmacogenetic information to individualize cancer therapy is feasi-
ble. Prior studies demonstrated that the DS rates for unselected pa-
tients with rectal cancer treated with CRT was 45% (range, 40% to
60%), with a pCR rate of 8% to 14%.2,7,8 By selecting a population
likely to respond to standard CRT using TYMS genotyping, DS and
ypT0 rates among patients with germline TSER *2/*2 or TSER *2/*3
were 64.4% and 20%, respectively. The DS rate was significantly better
than the predicted DS rate of 45% (P  .0001) and also higher than the
60% rate observed by Villafranca et al27 in that particular subset of
patients. The 18.9% pCR rate is higher than that reported by Sauer et
al2 (8%) and the National Surgical Adjuvant Breast and Bowel Project
R-03 study (15%)3 using only fluoropyrimidine with RT (Table 4).
Thirty percent of patients experienced grade 3 to 4 toxicities, also
comparable to that reported by Sauer et al2 for preoperative FU-
based CRT.2
On the basis of previous published results,27 we hypothesized
that patients homozygous for the TSER*3 allele would only have a
tumor DS rate of 22% with standard neoadjuvant FU-based CRT.
With chemotherapy intensification using weekly irinotecan added to
standard CRT in this study, the downstaging rate for poor-risk pa-
tients was significantly better than expected at 64.5% (P .0001). pCR
Table 4. Overview of Preoperative Chemoradiation Studies Using FU and Irinotecan
First Author/ Study
No. of










Sauer2 421 50.4 PVI 1,000 mg/m2/d 5 days a week  5 8 NA 27
Bosset4,34 506 45 350 mg/m2  LV 20 mg/m2, days 1-5
and 29-33
14 57 13
Gerard6 375 45 350 mg/m2  LV 20 mg/m2, days 1-5
and 29-33
11 NA 15
Brændengen5 98 50 400 mg/m2 bolus  LV 100 mg, days
1-2, 21-22, 35-36
16 NA 29
Aschele35 379 50.4 PVI 225 mg/m2/d 5 d a wk 16 NA 8




present study 90 45 PVI 225 mg/m2/d 5 days a week 19 64 30
FU  irinotecan-based
neoadjuvant CRT
Mehta36 32 50.4 PVI 200 mg/m2/d , days 1-33 50 mg/m2 weekly  4 37 71 28
Klautke37 37 50.4 PVI 250 mg/m2, days 1-43 40 mg/m2 weekly  6 22 76 32
Navarro38 74 45 PVI 225 mg/m2/d, 5 days a week 50 mg/m2 weekly  5 14 49 14
Mohiuddin39 106 Arm 1: hyperfractionated RT 55.2 to
60 Gy at 1.2 Gy twice a day
Arm 1: PVI 225 mg/m2/d, 7 days a week 28 78 28
Arm 2: radiation therapy 50.4 to 54
Gy at 1.8 Gy per day
Arm 2: PVI 225 mg/m2/d 5 days a week Arm 2: 50 mg/m2
weekly  4
28 78 37
Glynne-Jones40 57 45 350 mg/m2  LV 20 mg/m2, days 1-5
and 29-33
Dose escalation: 6 to
20 mg/m2
21 41 12
Iles41 31 45 PVI: FU 200 mg/m2, daily over 5 weeks 60 mg/m2 weekly  4 29 79 13
Poor-risk group of
present study 37 45 PVI 225 mg/m2/d 5 days a week 50 mg/m2 weekly  5 36 65 46
Abbreviations: FU, fluorouracil; RT, radiotherapy; pCR, pathologic complete response; DS, downstaging; CRT, chemoradiotherapy; NA, not available; PVI, protracted
venous infusion; LV, leucovorin; NSABP, National Surgical Adjuvant Breast and Bowel Project.
Grade 3 to 4 diarrhea.
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and ypT0 were achieved in 35.5% and 42% of patients, respectively.
However, higher rates of grade 3 to 4 toxicities (54.3%) were observed
with the addition of irinotecan to CRT, with 34% of patients requiring
hospitalization during treatment.
Preclinical and clinical evidence suggests that the relationship
between TSER*3 allele and FU response is due to a transcriptional
effect that leads to a higher amount of TS protein responsible for FU
resistance.24-26 However, recent studies42,43 conducted in rectal cancer
showed that high levels of TS in the tumor was associated with a better
tumor response. The small number of patients included in these
studies and the variety of drugs used in their treatment (FU/oxaliplatin
and capecitabine/oxaliplatin) may contribute to the discrepancy with
our results.
Several studies evaluating the addition of irinotecan at doses
ranging from 40 to 60 mg/m2 with FU/CRT have also reported high
rates of DS and pCR rates37-41(Table 4). The Radiation Therapy On-
cology Group trial 001239 reported a DS rate of 78% and a ypCR rate of
28% among 53 patients treated with the chemotherapy intensification
arm using weekly irinotecan plus infusional FU-based CRT. However,
similar to our results, the addition of irinotecan also was associated
with high-dose delay rates (45%), enhanced acute hematologic and
nonhematologic grade 3 to 4 toxicities (12% and 45%, respectively),
and low rates of late toxicities.
A rational strategy is to select patients who require chemother-
apy intensification to achieve DS while sparing those who would
otherwise achieve good responses to standard CRT from the
greater toxicities associated with this approach. As a result of
genotype-directed individualized treatment, poor-risk patients
achieve the same DS, 3-year RFS, and OS as good-risk patients.
Compared with the 41% 3-year DFS for poor-risk patients treated
with standard CRT reported by Villafranca et al,27 poor-risk pa-
tients treated with irinotecan chemotherapy-intensified CRT
achieved a 72.4% 3-year RFS. Moreover, consistent with other
studies reporting better survival associated with DS,44-46 those with
tumor DS had better OS and DFS as compared with those with no
DS. Enrichment of the population predicted to respond well to
standard CRT also explains the significantly better-than-predicted
DS rates for good-risk patients. These favorable outcomes were
achieved without exposing these good-risk patients to undue tox-
icities associated with chemotherapy intensification, which consti-
tuted more than 70% of our study patients. In this study, the
chemotherapy intensification agent added to neoadjuvant therapy
for poor-risk patients was irinotecan. The benefit of irinotecan-
based CRT in good-risk patients was not assessed in our study. It is
unclear whether there is an association between TYMS genotype
and sensitivity or toxicity to irinotecan. Alternative neoadjuvant
regimens using oxaliplatin in combination with FU or capecitabine
did not seem to result in any significant benefit compared with
FU-based CRT alone in genotype-unselected patients.35,47 Whether
the addition of oxaliplatin or a biologic agent such as bevacizumab
or cetuximab to standard CRT will improve responses and out-
comes for either risk group is unclear. These strategies need to be
evaluated in future studies.
There have been few practice-changing studies of biomarkers in
oncology. Recently introduced predictive markers have relied on ret-
rospective trials in which there is dramatic discernment of clinical
outcome (ie, KRAS mutations). Although the positive results of the
present study are intriguing, a prospective randomized trial in which
patients in each genotype are treated with FU/RT or FU/RT plus
irinotecan should be undertaken to validate the use of TYMS genotyp-
ing to direct treatment selection in the clinical setting.
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